SAWAI PHARMACEUTICAL CO., LTD.
沢井製薬株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4555
No filings in 18+ monthsFY2020 (Mar 2021) · IFRS · consolidated Source: filing S100LRUC
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2020 (Mar 2021) runs Apr 1, 2020 – Mar 31, 2021.
| Gross margin | 38.7% |
|---|---|
| Operating margin | 10.1% |
| Net margin | 6.6% |
| Return on equity | 5.8%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 3.2% |
| Revenue growth (YoY) | 2.6% |
| EPS (basic) | ¥281.80 |
| EPS growth (YoY) | -36.0% |
| Current ratio | 2.56x |
| Equity ratio | 55.5% |
| Book value / share | ¥4,984.51 |
| Free cash flow | ¥10.7B |